Neoleukin Therapeutics (NASDAQ:NLTX) Stock Rating Lowered by Bank of America

Neoleukin Therapeutics (NASDAQ:NLTXGet Rating) was downgraded by analysts at Bank of America from a “buy” rating to an “underperform” rating in a note issued to investors on Monday, September 12th, The Fly reports.

Several other research analysts have also weighed in on NLTX. HC Wainwright lowered their price objective on shares of Neoleukin Therapeutics from $22.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, September 12th. Piper Sandler lowered their price target on Neoleukin Therapeutics from $25.00 to $6.00 in a research report on Friday, May 27th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Neoleukin Therapeutics in a research report on Wednesday, July 6th.

Neoleukin Therapeutics Price Performance

Shares of NASDAQ:NLTX traded down $0.00 during midday trading on Monday, hitting $0.95. The stock had a trading volume of 79,493 shares, compared to its average volume of 292,692. Neoleukin Therapeutics has a 12 month low of $0.80 and a 12 month high of $8.17. The business’s 50-day simple moving average is $1.07 and its 200-day simple moving average is $1.28.

Institutional Trading of Neoleukin Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. raised its holdings in Neoleukin Therapeutics by 1.1% in the 4th quarter. Point72 Asset Management L.P. now owns 1,010,790 shares of the company’s stock valued at $4,872,000 after acquiring an additional 10,790 shares during the period. Kestra Private Wealth Services LLC lifted its holdings in Neoleukin Therapeutics by 100.0% during the 1st quarter. Kestra Private Wealth Services LLC now owns 24,000 shares of the company’s stock worth $45,000 after purchasing an additional 12,000 shares during the last quarter. Walleye Capital LLC acquired a new stake in Neoleukin Therapeutics during the 1st quarter worth approximately $27,000. Adviser Investments LLC boosted its stake in Neoleukin Therapeutics by 39.7% in the 2nd quarter. Adviser Investments LLC now owns 65,404 shares of the company’s stock valued at $67,000 after purchasing an additional 18,587 shares during the period. Finally, PDT Partners LLC grew its holdings in Neoleukin Therapeutics by 90.0% in the 4th quarter. PDT Partners LLC now owns 39,462 shares of the company’s stock valued at $190,000 after buying an additional 18,688 shares in the last quarter. Institutional investors own 49.19% of the company’s stock.

About Neoleukin Therapeutics

(Get Rating)

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

Featured Articles

The Fly logo

Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.